NCT01439204View on ClinicalTrials.gov

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

PHASE1CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Abatacept (BMS-188667)

Solution for injection, Intravenous, 750 mg, Single dose, 1 day,

Trial Locations (1)

68154

Icon Clinical Pharmacology Unit, Llc, Omaha

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY